CIK 0001604821
- Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 010894487
- Phone
- +1 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,217 | $165.87 | $202K | 106,815 |
| 2025-01-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1 | $167.08 | $167 | 106,814 |
| 2025-01-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,115 | $165.87 | $517K | 103,699 |
| 2025-01-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2 | $167.08 | $334 | 103,697 |
| 2025-01-29 | Sheena Jonathan Director | Sale 10b5-1 | −1,053 | $165.87 | $175K | 260,104 |
| 2025-01-29 | Sheena Jonathan Director | Sale 10b5-1 | −1 | $167.16 | $167 | 260,103 |
| 2025-01-29 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,999 | $165.87 | $995K | 2,383,181 |
| 2025-01-29 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4 | $167.36 | $669 | 2,383,177 |
| 2025-01-29 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −1,041 | $165.87 | $173K | 216,752 |
| 2025-01-29 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −3,730 | $165.87 | $619K | 213,022 |
| 2025-01-29 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −2 | $167.20 | $334 | 213,020 |
| 2025-01-29 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,178 | $165.87 | $195K | 139,056 |
| 2025-01-29 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −4,020 | $165.87 | $667K | 135,486 |
| 2025-01-29 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −3 | $167.36 | $502 | 135,483 |
| 2025-01-29 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −913 | $165.87 | $151K | 146,317 |
| 2025-01-29 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −3,115 | $165.87 | $517K | 143,202 |
| 2025-01-29 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −2 | $167.39 | $335 | 143,200 |
| 2025-01-29 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −3,805 | $165.87 | $631K | 263,824 |
| 2025-01-29 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −3 | $167.31 | $502 | 263,821 |
| 2025-01-29 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −9,870 | $165.87 | $1.6M | 253,951 |
Page 56 of 85 · 1,682 trades